What’s the skinny behind the Repatha (Evolocumab) FOURIER trial results that were announced recently by Amgen?

This short slide deck explains the results of the Fourier trial results with Repatha (Evolocumab) and its likely impact on prescriptions

Slides in the pack:

1. Mechanism of action of PCSK9 inhibitors and statins
2. The history of PCSK9 inhibitors
3. Overview of FOURIER trial (Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk)
4. The FOURIER trial may establish the use of Repatha among high risk   patients, though insurance companies are looking for greater risk reductions
5. Given the insufficient reduction in risks, Amgen may have to further assuage payer concerns, and meanwhile, focus on marketing (discounts and refunds)
6. Impact of the FOURIER trial in the cholesterol reducer market
7. Statins are the mainstay of treatment for Hypercholesterolemia and Dyslipidemia
   
8. The FOURIER trial may establish Repatha’s advantages compared to current therapies
9. The FOURIER study may have relied on a weak statistical method
10. How are payers likely to view the results of this trial?